18F-2-Deoxy-d-Glucose Positron Emission Tomography-Computed Tomography in Lung Cancer

Seminars in Roentgenology

Volumn 46, Issue 3, 2011, Pages 208-223

  DeLappe, Eithne ^a   Dunphy, Mark ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR;

ADRENAL TUMOR; ARTICLE; BONE METASTASIS; BRAIN RADIOGRAPHY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION;

FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959885443     PISSN: 0037198X     EISSN: 15584658     Source Type: Journal    
DOI: 10.1053/j.ro.2011.02.008     Document Type: Article

References (177)

1. Erasmus J.J., Macapinlac H.A., Swisher S.G. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 2007, 110:2155-2168.
2. NCCN clinical practice guidelines in oncology, in Non-Small Cell Lung Cancer. Version 1, 2011 National Comprehensive Cancer Network, Accessed February 18th, 2011. http://www.nccn.com/patient-guidelines.html%23nsclc.
3. Ravenel J.G., Mohammed T.L., Movsas B., et al. ACR Appropriateness Criteria noninvasive clinical staging of bronchogenic carcinoma. J Thorac Imaging 2010, 25:W107-W111.
4. Silvestri G.A., Gould M.K., Margolis M.L., et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines. Chest 2007, 132:178S-201S. (2nd edition).
5. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:iv68-iv70. EGWG.
6. Delbeke D., Coleman R.E., Guiberteau M.J., et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006, 47:885-895.
7. Boellaard R., O'Doherty M.J., Weber W.A., et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200.
8. Yang W., Fu Z., Yu J., et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 2008, 61:35-43.
9. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361:32-39.
10. Cheng N.M., Yu C.T., Ho K.C., et al. Respiration-averaged CT for attenuation correction in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2009, 36:607-615.
11. Pfannenberg A., Aschoff P., Brechtel K., et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007, 34:36-44.
12. Antoch G., Freudenberg L.S., Egelhof T., et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002, 43:1339-1342.
13. Gilman M.D., Fischman A.J., Krishnasetty V., et al. Optimal CT breathing protocol for combined thoracic PET/CT. AJR Am J Roentgenol 2006, 187:1357-1360.
14. De Wever W., Stroobants S., Coolen J., et al. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009, 33:201-212.
15. Chang G., Chang T., Pan T., et al. Implementation of an automated respiratory amplitude gating technique for PET/CT: clinical evaluation. J Nucl Med 2010, 51:16-24.
16. Bettinardi V., Picchio M., Di Muzio N., et al. Detection and compensation of organ/lesion motion using 4D-PET/CT respiratory gated acquisition techniques. Radiother Oncol 2010, 96:311-316.
17. Berthelsen A.K., Holm S., Loft A., et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005, 32:1167-1175.
18. Schultz E.M., Sanders G.D., Trotter P.R., et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 2008, 63:335-341.
19. Swensen S.J., Silverstein M.D., Edell E.S., et al. Solitary pulmonary nodules: clinical prediction model versus physicians. Mayo Clin Proc 1999, 74:319-329.
20. Gould M.K., Fletcher J., Iannettoni M.D., et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?. ACCP evidence-based clinical practice guidelines. Chest 2007, 132:108S-130S. (2nd edition).
21. Gambhir S.S., Shepherd J.E., Shah B.D., et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998, 16:2113-2125.
22. Kubota K., Matsuzawa T., Fujiwara T., et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990, 31:1927-1932.
23. Kim S.K., Allen-Auerbach M., Goldin J., et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007, 48:214-220.
24. Hellwig D., Ukena D., Paulsen F., et al. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 2001, 55:367-377. [in German].
25. Hickeson M., Yun M., Matthies A., et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002, 29:1639-1647.
26. Gould M.K., Maclean C.C., Kuschner W.G., et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924.
27. Hashimoto Y., Tsujikawa T., Kondo C., et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2006, 47:426-431.
28. Ohba Y., Nomori H., Shibata H., et al. Evaluation of semiquantitative assessments of fluorodeoxyglucose uptake on positron emission tomography scans for the diagnosis of pulmonary malignancies 1 to 3 cm in size. Ann Thorac Surg 2009, 87:886-891.
29. Goudarzi B., Jacene H.A., Wahl R.L. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med 2008, 49:1585-1592.
30. Bar-Shalom R., Kagna O., Israel O., et al. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-d-glucose avidity on positron emission tomography/computed tomography. Cancer 2008, 113:3213-3221.
31. Patz E.F., Lowe V.J., Hoffman J.M., et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993, 188:487-490.
32. Scheuermann J.S., Saffer J.R., Karp J.S., et al. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network Experience. J Nucl Med 2009, 50:1187-1193.
33. O J.H., Yoo Ie.R., Kim S.H., et al. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med 2007, 48:15-21.
34. Soret M., Bacharach S.L., Buvat I. Partial-volume effect in PET Tumor Imaging. J Nucl Med 2007, 48:932-945.
35. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007, 55:79-87.
36. Marom E.M., Sarvis S., Herndon J.E., et al. T1 lung cancers: Sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002, 223:453-459.
37. Daniels C.E., Lowe V.J., Aubry M.-C., et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007, 131:255-260.
38. Higashi K., Ueda Y., Seki H., et al. Fluorine-18-FDG PET Imaging Is Negative in bronchioloalveolar Lung Carcinoma. J Nucl Med 1998, 39:1016-1020.
39. Heyneman L.E., Patz E.F. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002, 38:261-266.
40. Raz D.J., Kim J.Y., Jablons D.M. Diagnosis and treatment of bronchioloalveolar carcinoma. Curr Opin Pulm Med 2007, 13:290-296.
41. Arenberg D. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:306S-313S. (2nd edition).
42. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
43. Ohtsuka T., Nomori H., Watanabe K., et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006, 107:2468-2473.
44. Davies A., Tan C., Paschalides C., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007, 55:75-78.
45. Goodgame B., Pillot G.A., Yang Z., et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008, 3:130-134.
46. Hanin F.X., Lonneux M., Cornet J., et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33:819-823.
47. Cerfolio R.J., Bryant A.S., Ohja B., et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
48. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007, 110:1654-1664.
49. Vesselle H., Freeman J.D., Wiens L., et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007, 13:3255-3263.
50. Downey R.J., Akhurst T., Gonen M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2007, 133:1419-1427.
51. Matthies A., Hickeson M., Cuchiara A., et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002, 43:871-875.
52. Kubota K., Itoh M., Ozaki K., et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001, 28:696-703.
53. Demura Y., Tsuchida T., Ishizaki T., et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003, 44:540-548.
54. Houseni M., Chamroonrat W., Zhuang J., et al. Prognostic implication of dual-phase PET in adenocarcinoma of the Lung. J Nucl Med 2010, 51:535-542.
55. Xiu Y., Bhutani C., Dhurairaj T., et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007, 32:101-105.
56. Chen C.-J., Lee B.-F., Yao W.-J., et al. Dual-Phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol 2008, 191:475-479.
57. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC Cancer Staging Manual 2010, Springer, New York. (7 ed).
58. Kligerman S., Abbott G. A radiologic review of the new TNM classification for lung cancer. AJR Am J Roentgenol 2010, 194:562-573.
59. UyBico S.J., Wu C.C., Suh R.D., et al. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. RadioGraphics 2010, 30:1163-1181.
60. De Leyn P., Lardinois D., Van Schil P.E., et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007, 32:1-8.
61. Maziak D.E., Darling G.E., Inculet R.I., et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009, 151:221-228.
62. Detterbeck F.C., Jantz M.A., Wallace M., et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007, 132:202S-220S. (2nd edition).
63. Hoekstra C.J., Stroobants S.G., Hoekstra O.S., et al. The value of [18F]fluoro-2-deoxy-d-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003, 39:151-157.
64. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, 229:526-533.
65. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507.
66. De Wever W., Ceyssens S., Mortelmans L., et al. Additional value of PET-CT in the staging of lung cancer: Comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007, 17:23-32.
67. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997, 80:2505-2509.
68. Lee J.A. Segmentation of positron emission tomography images: Some recommendations for target delineation in radiation oncology. Radiother Oncol 2010, 96:302-307.
69. De Ruysscher D., Kirsch C.M. PET scans in radiotherapy planning of lung cancer. Radiother Oncol 2010, 96:335-338.
70. Thorwarth D., Geets X., Paiusco M. Physical radiotherapy treatment planning based on functional PET/CT data. Radiother Oncol 2010, 96:317-324.
71. Dwamena B.A., Sonnad S.S., Angobaldo J.O., et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999, 213:530-536.
72. Toloza E.M., Harpole L., McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003, 123:137S-146S.
73. Meyers B.F., Haddad F., Siegel B.A., et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 2006, 131. 822-822.
74. Arita T., Kuramitsu T., Kawamura M., et al. Bronchogenic carcinoma: Incidence of metastases to normal sized lymph nodes. Thorax 1995, 50:1267-1269.
75. Kerr K.M., Lamb D., Wathen C.G., et al. Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax 1992, 47:337-341.
76. Kalff V., Hicks R.J., MacManus M.P., et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111-118.
77. Dietlein M., Weber K., Gandjour A., et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000, 27:1598-1609.
78. Patz E.F., Lowe V.J., Goodman P.C., et al. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995, 108:1617-1621.
79. Wahl R.L., Quint L.E., Greenough R.L., et al. Staging of Mediastinal non-small cell lung cancer with FDG-CT, PET, and fusion images: preliminary prospective evaluation. Radiology 1994, 191:371-377.
80. Steinert H.C., Hauser M., Allemann F., et al. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997, 202:441-446.
81. von Haag D.W., Follette D.M., Roberts P.F., et al. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002, 103:160-164.
82. Shim S.S., Lee K.S., Kim B.T., et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005, 236:1011-1019.
83. Yi C.A., Lee K.S., Kim B.-T., et al. Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer. AJR Am J Roentgenol 2007, 188:318-325.
84. Tournoy K.G., Maddens S., Gosselin R., et al. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007, 62:696-701.
85. Kim B.-T., Lee K.S., Shim S.S., et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT-a prospective study. Radiology 2006, 241:501-509.
86. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005, 128:2289-2297.
87. Cerfolio R.J., Ojha B., Bryant A.S., et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004, 78:1017-1023. discussion: 1017-1023.
88. Rosell R., Gomez-Codina J., Camps C., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 26:7-14.
89. Roth J.A., Atkinson E.N., Fossella F., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998, 21:1-6.
90. Nagai K., Tsuchiya R., Mori T., et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003, 125:254-260.
91. Song W.A., Zhou N.K., Wang W., et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010, 5:510-516.
92. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
93. Pisters K.M., Ginsberg R.J., Giroux D.J., et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000, 119:429-439.
94. Al-Sarraf N., Aziz R., Gately K., et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008, 33:104-109.
95. Lee P.C., Port J.L., Korst R.J., et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007, 84:177-181.
96. Cerfolio R.J., Bryant A.S., Eloubeidi M.A. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest 2006, 130:1791-1795.
97. Hishida T., Yoshida J., Nishimura M., et al. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax 2008, 63:526-531.
98. de Langen A.J., Raijmakers P., Riphagen I., et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29:26-29.
99. Melek H., Gunluoglu M.Z., Demir A., et al. Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33:294-299.
100. Herth F.J., Eberhardt R., Krasnik M., et al. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008, 133:887-891.
101. Gomez-Caro A., Garcia S., Reguart N., et al. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg 2010, 37:1168-1174.
102. Cerfolio R.J., Ojha B., Bryant A.S., et al. The accuracy of integrated PET-CT compared with dedicated pet alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004, 78:1017-1023.
103. Yoon Y.C., Lee K.S., Shim Y.M., et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003, 227:764-770.
104. Karam M., Roberts-Klein S., Shet N., et al. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology. J Nucl Med 2008, 49:1429-1436.
105. Uesaka D., Demura Y., Ishizaki T., et al. Evaluation of dual-time-point 18F-FDG PET for Staging in patients with Lung Cancer. J Nucl Med 2008, 49:1606-1612.
106. Carnochan F.M., Walker W.S. Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg 2009, 35:781-785.
107. Coleman R.E., Delbeke D., Guiberteau M.J., et al. Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the Joint Working Group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Am Coll Radiol 2005, 2:568-584.
108. Weder W., Schmid R.A., Bruchhaus H., et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66:886-892; discussion: 892-883 1998.
109. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001, 50:287-293.
110. Eschmann S.M., Friedel G., Paulsen F., et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002, 29:804-808.
111. Marom E.M., McAdams H.P., Erasmus J.J., et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999, 212:803-809.
112. Quint L.E., Tummala S., Brisson L.J., et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996, 62:246-250.
113. Altundag O., Stevens C., Rice D.C., et al. The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: a retrospective analysis. J Clin Oncol 2005, ASCO Annual Meeting Proceedings 23:9568, 2005, Accessed February 18, 2011. http://www.asco.org/ascov2/Meetings/Abstracts?%26vmview=abst_detail_view%26confID=34%26abstractID=34179.
114. Erasmus J.J., McAdams H.P., Rossi S.E., et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000, 175:245-249.
115. Gupta N.C., Rogers J.S., Graeber G.M., et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002, 122:1918-1924.
116. Duysinx B.C., Larock M.P., Nguyen D., et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun 2006, 27:971-976.
117. Duysinx B., Corhay J.L., Larock M.P., et al. Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion. Nucl Med Commun 2008, 29:982-986.
118. Nguyen N.C., Tran I., Hueser C.N., et al. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med 2009, 34:886-890.
119. Toaff J.S., Metser U., Gottfried M., et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol 2005, 40:204-209.
120. Kwek B.H., Aquino S.L., Fischman A.J. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004, 125:2356-2360.
121. Shim S.S., Lee K.S., Kim B.T., et al. Integrated PET/CT and the dry pleural dissemination of peripheral adenocarcinoma of the lung: diagnostic implications. J Comput Assist Tomogr 2006, 30:70-76.
122. Grassetto G., Fornasiero A., Bonciarelli G., et al. Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol 2010, 12:139-144.
123. Campistron M., Rouquette I., Courbon F., et al. Adenoid cystic carcinoma of the lung: interest of 18FDG PET/CT in the management of an atypical presentation. Lung Cancer 2008, 59:133-136.
124. Kim K.S., Na K.J., Kim Y.H., et al. Surgically resected isolated hepatic metastasis from non-small cell lung cancer: a case report. J Thorac Oncol 2006, 1:494-496.
125. Gross BH, Brown RKJ, Kalemkerian GP: Optimal anatomic coverage for CT in staging lung cancer: Lessons from PET-CT correlation. Lung Cancer, in press.
126. Kinkel K., Lu Y., Both M., et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002, 224:748-756.
127. Fong Y., Saldinger P.F., Akhurst T., et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999, 178:282-287.
128. Ruers T.J., Langenhoff B.S., Neeleman N., et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002, 20:388-395.
129. Blake M.A., Slattery J.M.A., Kalra M.K., et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006, 238:970-977.
130. Erasmus J., Patz E., McAdams H., et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997, 168:1357-1360.
131. Groussin L., Bonardel G., Silvera S., et al. 18F-fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective Study in 77 operated patients. J Clin Endocrinol Metab 2009, 94:1713-1722.
132. Metser U., Miller E., Lerman H., et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006, 47:32-37.
133. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21:1285-1292.
134. Vikram R., Yeung H.D.W., Macapinlac H.A., et al. Utility of PET/CT in Differentiating Benign from Malignant Adrenal Nodules in patients with Cancer. AJR Am J Roentgenol 2008, 191:1545-1551.
135. Mackie G.C., Shulkin B.L., Ribeiro R.C., et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006, 91:2665-2671.
136. Elaini A.B., Shetty S.K., Chapman V.M., et al. Improved detection and characterization of adrenal disease with PET-CT. RadioGraphics 2007, 27:755-767.
137. Ichiya Y., Kuwabara Y., Sasaki M., et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996, 10:193-200.
138. Choi N.C., Fischman A.J., Niemierko A., et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 54:1024-1035.
139. Michaelis L.C., Ratain M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006, 6:409-414.
140. Parulekar W.R., Eisenhauer E.A. Novel endpoints and design of early clinical trials. Ann Oncol 2002, 4(13 suppl):139-143.
141. Schilsky R.L. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002, 8:935-938.
142. Van den Abbeele A.D. The lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 2008, 2(13 suppl):8-13.
143. Hellwig D., Graeter T.P., Ukena D., et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004, 128:892-899.
144. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998, 9:1193-1198.
145. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
146. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066.
147. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 1(50 suppl):122S-150S.
148. Yau Y.Y., Chan W.S., Tam Y.M., et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?. J Nucl Med 2005, 46:283-291.
149. An Y.S., Sheen S.S., Oh Y.J., et al. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer. Ann Nucl Med 2007, 21:585-592.
150. Mawlawi O., Erasmus J.J., Munden R.F., et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 2006, 186:308-319.
151. Brenner D.J., Hall E.J. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007, 357:2277-2284.
152. Teo B.K., Badiee S., Hadi M., et al. Correcting tumour SUV for enhanced bone marrow uptake: Retrospective 18F-FDG PET/CT studies. Nucl Med Commun 2008, 29:359-366.
153. Akhurst T., Downey R.J., Ginsberg M.S., et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002, 73:259-264. discussion: 264-256.
154. Ryu J.S., Choi N.C., Fischman A.J., et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology. Lung Cancer 2002, 35:179-187.
155. Cerfolio R.J., Ojha B., Mukherjee S., et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003, 125:938-944.
156. Port J.L., Kent M.S., Korst R.J., et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004, 77:254-259. discussion: 259.
157. De Leyn P., Stroobants S., De Wever W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: A Leuven Lung Cancer Group Study. J Clin Oncol 2006, 24:3333-3339.
158. Cerfolio R.J., Bryant A.S., Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 2006, 2006:1229-1235.
159. Milano S., Zorzi F., Marini G., et al. Histopathological grading of response to induction chemotherapy in non-small cell lung cancer: A preliminary study. Lung Cancer 1996, 15:183-187.
160. Pöttgen C., Levegrün S., Theegarten D., et al. Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006, 12:97-106.
161. Dooms C., Verbeken E., Stroobants S., et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008, 26:1128-1134.
162. Cerfolio R.J., Bryant A.S., Winokur T.S., et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004, 78:1903-1909.
163. Port J.L., Kent M.S., Korst R.J., et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004, 77:254-259.
164. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic Relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clinl Oncol 2005, 23:8362-8370.
165. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:8362-8370.
166. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998, 9:1193-1198.
167. Eschmann S.M., Friedel G., Paulsen F., et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007, 55:165-171.
168. Nahmias C., Hanna W.T., Wahl L.M., et al. Time Course of Early Response to Chemotherapy in non-small Cell Lung Cancer patients with 18F-FDG PET/CT. J Nucl Med 2007, 48:744-751.
169. de Geus-Oei L.-F., van der Heijden H.F.M., Visser E.P., et al. Chemotherapy Response Evaluation with 18F-FDG PET in patients with non-small Cell Lung Cancer. J Nucl Med 2007, 48:1592-1598.
170. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657.
171. Tanvetyanon T., Eikman E.A., Sommers E., et al. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008, 26:4610-4616.
172. Bruzzi J.F., Munden R.F. PET/CT imaging of lung cancer. J Thorac Imaging 2006, 21:123-136.
173. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001, 42:1605-1613.
174. Roberts K.B., Manus M.P., Hicks R.J., et al. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005, 47:49-57.
175. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: Diagnostic value and impact on patient management. J Nucl Med 2004, 45:1640-1646.
176. Inoue T., Kim E.E., Komaki R., et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995, 36:788-793.
177. Bury T., Corhay J.L., Duysinx B., et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999, 14:1376-1380.